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Abstract
Objectives—To determine the impact of tuberculosis (TB) treatment at the time of combination 
antiretroviral therapy (cART) initiation on virologic and CD4 count response to cART.
Methods—Systematic review and meta-analysis of studies reporting HIV RNA and CD4 count 
response, stratified by TB treatment status at cART initiation. Stratified random-effects and meta-
regression analyses were used when possible.
Results—25 eligible cohort studies reported data on 49,578 (range 42-15,646) adults, of whom 
8,826 (18%) were receiving TB treatment at cART initiation. 17 studies reported virologic 
response; 21 reported CD4 count response. The summarized random-effects relative risk (RRRE) 
of virologic suppression in those receiving vs. not receiving TB treatment at different time points 
following cART initiation was 1.06 (0.86-1.29) at 1-4 months, 0.91 (0.83-1.00) at 6 months, 0.99 
(0.94-1.05) at 11-12 months, and 0.99 (0.77-1.28) at 18-48 months. The overall RRRE at 1-48 
months was 0.97 (95% CI:0.92-1.03). Available data regarding the effect of TB treatment on 
virologic failure were heterogeneous and inconclusive (13 estimates). Differences in median CD4 
count gain between those receiving vs. not receiving TB treatment ranged from -10 to 60 cells/μL 
(median 27) by 6 months (7 estimates) and -10 to 29 (median 6) by 11-12 months (5 estimates), 
though the heterogeneity of the response measures did not support meta-analysis.
Conclusions—Patients receiving TB treatment at cART initiation experience similar virologic 
suppression and CD4 count reconstitution as those not receiving TB treatment, reinforcing the 
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need to start cART during TB treatment and allowing more confidence in clinical decision-
making.
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HIV; tuberculosis; antiretroviral therapy; viral load; CD4 lymphocyte count; systematic review; 
adults
Introduction
Tuberculosis (TB) threatens the health of people living with HIV (PLWH). Globally in 
2011, 13% of incident TB cases were co-infected with HIV and an estimated 0.4 million TB 
deaths occurred among PLWH [1]. Given the World Health Organization's 2010 
recommendation that all PLWH with TB be initiated on combination antiretroviral therapy 
(cART), regardless of CD4 count [2], and the goal of 100% cART coverage of co-infected 
patients by 2015 [3], many individuals are initiating cART while concurrently on TB 
therapy. PLWH who are also being treated for TB may experience a differential response to 
cART due to drug-drug interactions [4, 5], an increased risk of drug toxicity [4, 5], immune 
reconstitution inflammatory syndrome [6], and the potential for lower adherence due to the 
high pill burden [5]. The effect of TB treatment and its associated potential challenges and 
complications regarding a patient's response to cART require careful evaluation.
We aimed to describe the impact of receiving TB treatment at the time of cART initiation on 
virologic and CD4 count response to cART among HIV-infected adults. In addition, we 
highlighted the various outcome measures used in the literature and make recommendations 
for some methodological standards that may ease future between-study comparisons.
Methods
Search strategy and selection criteria
To investigate the effect of TB treatment at time of cART initiation on virologic response 
and CD4 count response, we carried out a systematic and sensitive search using an a priori 
protocol developed according to PRISMA guidelines [7]. We searched PubMed and 
EMBASE, as well as abstract databases from the 2009 to 2012 Conferences on Retroviruses 
and Opportunistic Infections, International Union Against Tuberculosis and Lung Disease 
World Conferences on Lung Health, and International AIDS Society conferences. The 
search terms “HIV AND Tuberculosis AND (Viral Load OR CD4 lymphocyte count OR 
Mortality) AND Antiretroviral therapy” were used to identify relevant articles in PubMed 
and EMBASE. Searches were performed on January 29, 2013 and included original human 
subjects studies published since 1997 (the start of the cART era). Additional articles were 
identified from reference lists, reviews, and Web of Science citation lists.
H.M.S. and A.V.R. independently reviewed titles and abstracts of original studies retrieved 
by the search. H.M.S. reviewed full-text and references of selected articles. H.M.S. and 
M.R.P. independently abstracted study data from full reports; discrepancies were resolved 
by consensus among co-authors.
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Studies were included if they reported HIV RNA and/or CD4 count response following 
cART initiation among antiretroviral treatment-naïve HIV-infected adults, stratified by TB 
treatment status at cART initiation. Studies with ≤5% antiretroviral-experienced patients or 
patients only previously exposed to a single intrapartum dose of nevirapine were also 
included. Studies of children <14 years of age were excluded. No additional exclusion 
criteria or language restrictions were imposed.
Data extraction
The following information, if available, was abstracted from each article: first author 
surname; publication year; study dates; geographic location; study design; clinical setting; 
sample size; number receiving and not receiving TB treatment at cART initiation; if TB 
treatment was the main exposure of interest; types of TB included; culture confirmation of 
TB cases; TB site; timing of TB treatment in relation to cART initiation; length of follow-
up; proportion antiretroviral-naïve; percentage male; mean or median participant age; 
criteria for cART initiation; cART regimen; baseline median CD4 count and HIV RNA; 
HIV RNA outcome measure(s); CD4 count outcomes measure(s); covariate adjustment; 
exclusion criteria; proportion lost-to-follow-up; and how each study handled loss-to-follow-
up, mortality, and regimen switching. For this purposes of this review, we abstracted results 
as presented in the specific studies according to their individual methods and assumptions.
Statistical analysis
Reported effect estimates over any length of time were abstracted. If only count data of 
those who experienced an outcome, stratified by TB treatment status, were reported, a risk 
ratio (RR) and 95% confidence interval (CI) were calculated. If a study reported an outcome 
only graphically, outcome values were visually estimated [8]. Standard error estimates were 
inferred from reported CIs by [ln(upper limit) – ln(lower limit)]/3.92 [9]. As we aimed to 
quantify virologic suppression, if a study reported on patients who failed to suppress, this 
information was converted to obtain data on suppression. For CD4 counts, if 2 of 3 of the 
following measures were reported, we calculated the third measure: mean baseline CD4 
count, mean change in CD4 count from baseline, mean absolute CD4 count. We were unable 
to calculate the missing measures if only median CD4 counts were reported.
For virologic suppression, summarized relative risks were calculated using random-effects 
summarization with unconditional variances and the method of moments estimated between-
study variance (τ2) [8]. As several studies reported estimates at multiple of time points, we 
used the estimate closest to the midpoint of each study's follow-up time to get an overall 
relative risk for virologic suppression. In addition, to examine short- and long-term virologic 
suppression, summary relative risks at 1-4 months, 6 months, 11-12 months and 18-48 
months were calculated. The p-values for a standard chi-square homogeneity test statistic 
were used to assess overall consistency among the effect estimates across studies. τ2 was 
used to calculate 95% population effects intervals [10] (where 95% of populations are 
estimated to have their means), opposite effects proportions [11] (proportion of populations 
likely to experience a relative risk below unity), and 95% prediction intervals [11] (95% of 
these intervals will cover the true value estimated by a future study). Stratified and random-
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effects meta-regression analyses were used to calculate stratum-specific summary measures 
and 95% CIs, along with ratios of the stratum-specific RRs as described by Bassler [12].
Funnel plots of ln(virologic suppression relative risk) vs. the inverse-variance weight of 
studies were visually examined for asymmetry and statistically assessed using methods 
proposed by Begg [13] and Egger [14] and the trim-and-fill method [15]. STATA (version 
12, Stata corporation, College Station, TX) was used for these analyses.
Results
Selected studies
990 unique abstracts were reviewed: 795 from PubMed, 143 from EMBASE, and 52 from 
conference proceedings (Fig. 1). Of these, 120 full-text articles were selected for review. In 
total, 18 articles [16-33] and five conference abstracts [34-38] were eligible. Five additional 
articles met our inclusion criteria: two from reference lists [39, 40] and three from Web of 
Science citation searches [41-43]. One included abstract [34] was subsequently published as 
a full article [44]; only data from the full article was included. Three eligible studies were 
excluded: one because some patients included in the TB treatment-exposed group had 
completed TB treatment just prior to cART initiation [36], and two because they included 
some early incident TB cases in their TB treatment-exposed group [20, 31]. Articles 
reporting on the same study population, but at differing time points following cART 
initiation, were retained [26, 27, 39]. Similarly, we retained both reports of a Tanzanian 
cohort [22, 42].
Study and population characteristics
The 25 final studies provided data on 49,578 PLWH, of which 8,826 (18%) were receiving 
TB treatment at cART initiation. Selected study and population characteristics are displayed 
in Table 1. All were cohort studies; four reported virologic response, eight reported CD4 
count response, and 13 reported both outcomes. While the majority of studies was based in 
Sub-Saharan Africa, nine included Asian populations [17, 23, 26, 27, 29, 32, 33, 38, 39] and 
three were from Europe or North America [19, 21, 28]. Most publications assessed response 
to cART, regardless of regimen type, though some reported estimates specific to nevirapine-
[18, 26, 27, 30, 39] or efavirenz-based [18, 22, 25, 29, 30, 42] cART (see Supplemental 
Digital Content 1, which provides study-specific details on cART regimens). Though 
included studies used a variety of cART regimens, nevirapine was often used in combination 
with stavudine and efavirenz was often used in combination with zidovudine and 
lamivudine. All studies used cART initiation as the time origin, except one which began at 
the commencement of cART education and adherence sessions, with most patients starting 
cART a month or two later [44]. Two studies included women previously exposed to a 
single intrapartum dose of nevirapine [18, 40], and one study included 3% antiretroviral-
experienced patients [17].
Seventeen studies examined TB treatment at cART initiation as the main exposure of 
interest [18, 19, 21, 23, 25-27, 29, 30, 32, 33, 35, 37-39, 43, 44]. The other eight studies 
examined TB treatment as a secondary exposure; five aimed to describe general cART 
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outcomes [16, 24, 28, 40, 41], and one each examined the primary exposures of timeliness 
of clinic attendance [17], β-defensin genomic copy number [22], and liver enzyme 
abnormalities [42]. The type of TB being treated varied across studies. Only one study had a 
subset of bacteriologically-confirmed TB cases [44], while others included both confirmed 
and probable TB cases. One study focused solely on pulmonary TB [32], and three excluded 
patients who developed incident TB from the reference group [18, 30, 35]. Sixteen studies 
reported detail on the duration of TB treatment at the time of cART initiation (see Table, 
Supplemental Digital Content 2, which provides study-specific information on the timing of 
TB treatment, if available).
Overall loss-to-follow-up was reported by 15 studies and ranged from 0% to 64% (median 
10%, interquartile range 7% to 12%) (see Table, Supplemental Digital Content 3, which 
details methods utilized by studies to handle loss-to-follow-up and mortality). 5 studies 
limited their analysis to those who completed follow-up [16, 30, 35, 37, 44] and 3 studies 
considered those who discontinued cART for a variety of reasons and/or lacked follow-up 
laboratory data as treatment failures [21, 26, 27]. While most studies did not describe how 
they handled patients who switched cART regimens, one excluded patients who stopped or 
changed cART during follow-up [18], three explicitly retained patients who switched [24, 
30, 40], and one did a sensitivity analysis considering those who discontinued stavudine as 
treatment failures [27].
All studies included both genders, with the proportion male ranging from 21% to 92% 
(median 45%). All patients were ≥14 years of age; mean patient age ranged from 31 to 41 
years (median 36). Median baseline CD4 count ranged from 29 to 196 cells/μL (median 94), 
and baseline HIV RNA ranged from 4.9 to 5.8 log10 copies/mL (median 5.3). One study 
reported results stratified by baseline CD4 count [33].
Virologic suppression
There was heterogeneity in how each study quantified virologic response with respect to the 
reported effect measure, the cut-off used (50 or 400 copies/mL), and the timing of 
measurement (see Table, Supplemental Digital Content 4 for virologic measures as reported 
by each study). In total, 17 studies reported virologic suppression, either directly or as a 
measure that allowed conversion into virologic suppression. Times of reported virologic 
suppression ranged from 1 to 48 months following cART initiation, with some studies 
reporting multiple time points. While most studies had overall suppression proportions 
>75%, several observed relatively low suppression. The study with the shortest follow-up 
time (1 month) reported the lowest overall proportion suppressed (46%) [23]. Manosuthi et 
al. (2006, 2008, 2010) also reported low suppression among Thai patients: 69% at 6 months 
[39], 59% at 33 months [26] and 51% at 48 months [27]. Three other studies reported 
suppression rates between 64 and 70% [16, 21, 32]. However, three of these studies that 
reported low suppression rates considered those who discontinued cART or lacked follow-
up laboratory data as treatment failures [21, 26, 27].
In total, 15 studies reported RRs for virologic suppression in those receiving vs. not 
receiving TB treatment at cART initiation (Fig. 2). Overall, the random-effects relative risk 
(RRRE) for suppression was 0.97 (95% CI 0.92-1.03). When estimates were categorized 
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according to follow-up time, the RRRE for suppression was 1.06 (0.86-1.29) at 1-4 months, 
0.91 (0.83-1.00) at 6 months, 0.99 (0.94-1.05) at 11-12 months, and 0.99 (0.77-1.28) at 
18-48 months after cART initiation (Table 2). In meta-regression analysis, a lower limit of 
detection of 50 or 400 copies/mL and type of cART regimen did not substantially influence 
the summary relative risks (see Table, Supplemental Digital Content 5 for meta-regression 
results).
Additionally, 6 studies provided data on cART regimen-specific relative risks of virologic 
suppression (see Figure, Supplemental Digital Content 6 for forest plot). The three lowest 
RRs for TB treatment exposure all correspond to three follow-up time-points of the 
nevirapine-based cART arm of Boulle et al. (2008) [18].
The funnel plot of overall suppression relative risks did not appear asymmetrical due to 
publication bias or other factors, with Begg's and Egger's p-values for small study effects of 
0.26 and 0.71, respectively (see Figure, Supplemental Digital Content 7, for the funnel plot).
Virologic failure
Measures of virologic failure were highly heterogeneous (Supplemental Digital Content 4), 
with studies measuring whether patients reached HIV RNA levels of >5000 copies/mL [17], 
failed to suppress <400 copies/mL [18], rebounded after being previously undetectable or 
never became undetectable [23, 25, 26], time to first value ≥400 [18], time to 2 consecutive 
values ≥5000 copies/mL [18], and time to first value >500 among those who initially 
suppressed [28]. Six of these studies did not find TB treatment to have a significant effect on 
virologic failure [17, 18, 23, 25, 26, 40]. Interestingly, Boulle et al. found an association 
between TB treatment and virologic failure among those on nevirapine-based cART, but not 
among patients on efavirenz-based cART in their 2008 study [18], but reported the opposite 
finding in their 2010 study [40]. The substantial heterogeneity among virologic failure 
outcome measures precluded a formal meta-analysis.
CD4 count response to cART
Methods for measuring and reporting CD4 count response were even more heterogeneous 
than those used for virologic response, due to measurements at different time points and use 
of a diversity of outcome measures. Eight studies reported mean or median change in CD4 
count from baseline, five measured mean or median absolute CD4 count during follow-up, 
and three reported the difference in CD4 count gain from baseline in patients receiving vs. 
not receiving TB treatment at cART initiation (Table 3). In addition, some studies defined a 
specific measure of immunologic success [21, 24] or immunologic failure [24, 41], and two 
studies described the CD4 count recovery trajectory [24, 43] (see Table, Supplemental 
Digital Content 8 for detailed immunologic measures). Two studies limited reporting of 
CD4 count response to virologically suppressed patients [24, 40].
Overall, those receiving TB treatment at cART initiation tended to have lower baseline CD4 
counts, greater increases in CD4 count from baseline, and lower absolute CD4 counts during 
follow-up. Median change in CD4 count from baseline after 6 months of cART (reported by 
7 studies) ranged from 97 to 200 cells/μL (median 167) among TB treatment-exposed 
patients and from 89 to 177 cells/μL (median 138) among those not on TB treatment. At 
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11-12 months, median change in CD4 count from baseline (reported by 5 studies) ranged 
from 124 to 234 cells/μL (median 155) among TB treatment-exposed patients and from 104 
to 205 cells/μL (median 165) among those not on TB treatment. This corresponds to a 
differential gain in CD4 count between patients receiving vs. not receiving TB treatment at 
cART initiation ranging from -10 to 60 more CD4 cells/μL (median 27) at 6 months and -10 
to 29 more CD4 cells/μL (median 6) at 11-12 months. Heterogeneity among CD4 count 
response outcomes measures prevented formal meta-analysis.
Discussion
In this systematic review and meta-analysis of the effect of TB treatment on virologic and 
CD4 count response to cART, the first meta-analysis of this topic to our knowledge, we 
found that exposure to TB treatment at cART initiation does not impair virologic 
suppression or CD4 count gain. The effect on the risk of virologic failure could not be 
assessed. Our findings indicate that despite concerns about drug-drug interactions, toxicity, 
high pill burden, and IRIS, TB treatment does not appear to reduce the efficacy of cART in 
regards to virologic suppression and CD4 count response. The reported outcome measures 
were however highly heterogeneous, impeding sound between-study comparisons or meta-
analytic summarization for outcome measures other than virologic suppression. While 
rigorous meta-analysis methods could not be applied for CD4 response, we did observe 
similar within-study effects of TB treatment, and the overall impression is that TB treatment 
exposure does not have a substantial impact on CD4 recovery.
Furthermore, time points reported by individual studies were also heterogeneous. The 
optimal time point for evaluating the effect of exposure to TB treatment on response to 
cART is unclear. Follow-up times shorter than 4 months may be too early to accurately 
describe response to cART, and follow-up times longer than two years may underestimate 
the impact of TB treatment at cART initiation, especially if patients who switch treatments 
or take second-line therapy are included in the analysis. For the sake of completeness, all 
reported outcome measures and follow-up times were retained in this review.
The exposure, TB treatment at cART initiation, captured both exposure to active TB disease 
and exposure to anti-tuberculosis drugs. This combined exposure is useful from a health 
systems perspective, particularly in low-resource countries, where active TB cannot always 
be confirmed, especially in PLWH. This is further highlighted by the fact that the included 
studies used a variety of methods for determining who had active TB and should receive 
treatment, and no studies were limited to bacteriologically-confirmed TB cases and only one 
study described this subset. Consequently, active TB could have been misclassified and 
some patients included in this meta-analysis may have received TB treatment even though 
they did not have TB.
Since being treated for active TB cannot be studied in a randomized controlled trial, all 
studies included in our review were observational. Consequently, there was much 
heterogeneity in the duration of TB treatment prior to cART initiation, with some patients on 
TB therapy for up to eight months and others beginning TB treatment and cART 
concurrently. While the timing of TB treatment in relation to cART initiation is an important 
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factor when evaluating mortality [45-49], it is unclear whether TB treatment timing would 
influence virologic or CD4 count response. Unfortunately, the included studies did not 
provide enough information on duration of TB treatment to systematically evaluate its effect 
on our results. Similarly, a lack of provided data on cART regimen switching during follow-
up precluded a systematic evaluation of this factor.
This systematic review and meta-analysis may have been subject to some biases. First, 
virologic and immunologic response cannot be evaluated in those who have died or were 
lost-to-follow-up. Loss rates varied widely, ranging from 0% to 64% though most studies 
lost ≤12%, and studies handled loss-to-follow-up in a variety of ways, which may have 
influenced their results. Missing patients may systematically differ from those retained in the 
analysis. If response to cART among lost or deceased patients was differential by TB 
treatment status, than the results of these studies and our review could have been biased. 
Second, in 8 of 25 studies, TB treatment was not the primary exposure and covariates 
included in some multivariable models may differ from ideal confounder adjustment for this 
research question. Third, some bias may have been introduced by estimation methods used 
when a study did not directly report an outcome measure but provided the necessary data to 
calculate the desired effect measures [8, 9].
In conclusion, this recent comprehensive review of studies assessing the effect of TB 
treatment on response to cART indicates that TB treatment does not affect virologic 
suppression or CD4 count gain after cART initiation and we were unable to assess the effect 
on virologic failure. These findings will allow health care workers to be more confident in 
their clinical decision-making and in their communication to patients about the need to start 
cART during TB treatment. The heterogeneity in outcome measures posed a challenge to the 
interpretation and summarization of the virologic and CD4 count response to cART. 
Between-study comparisons could be greatly facilitated by methodological standardization 
of outcome measures and their time points in future studies.
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Figure 1. Identification and selection of eligible studies
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Relative risk of virologic suppression in those receiving vs. not receiving tuberculosis 
treatment at cART initiation by length of follow-up time, as reported by 15 studies. 
Estimates were abstracted according to the precision and stratification used by the original 
authors. Estimates calculated using available data are reported to 2 decimal places. 
Abbreviations: cART, combination antiretroviral therapy; CI, confidence interval; EFV, 
efavirenz; NR, not reported; NVP, nevirapine; RR, relative risk.
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Table 3
Types of outcome measures used by 21 studies to quantify CD4 count response to cART
Measure of CD4 count response
Number of studies 
reporting this 
measure
Length of follow-up used 
in reporting this measure 
(months)
Immunologic success
 Change in CD4 count from baselinea 8 1; 3; 6; 9; 11; 12
 Absolute CD4 count at a specific follow-up timeb 5 3; 6; 9; 11; 48
 Difference in the increase in CD4 count from baselinec 3 6; 18; 22
 Increase of ≥50 cells/μL from baseline 1 6
 Increase of ≥100 cells/μL from baseline 1 12
 Absolute CD4 count >200 cells/μL 1 12
 Absolute CD4 count >500 cells/μL 1 30
 Rate of CD4 count increase from baseline (cells/month) 1 30
 Difference in CD4 count recovery slope (cells/6 months) 1 6; 48
 Median on treatment peak CD4 count 1 53
 Median change between baseline and on treatment peak CD4 count 1 53
Immunologic failure
 CD4 count decline from baseline, CD4 count <100 cells/μL, or 50% decline from 
peak CD4 count after ≥6 months of cART
1 36
 Rate of immunologic failure 1 36
 Absolute CD4 count <500 cells/μL 1 30
Abbreviations: cART, combination antiretroviral therapy
a
An additional 2 studies provided data that enabled the calculation of this measure.
b
An additional 3 studies provided data that enabled the calculation of this measure.
c
An additional 10 studies provided data that enabled the calculation of this measure.
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